Sign in
TerminatedPhase 1

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

Key facts

Who runs it
University of Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
42 people enrolled
Started
24 Jan 2024
Ended
12 May 2025
Type of study
Interventional, 5 groups
Treatments tested
  • Xevinapant
  • Carboplatin
  • Paclitaxel
  • Radiation Therapy
Record updated
31 March 2026
Why it stopped
Drug no longer being developed by manufacturer

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (24)Hide the full registry criteria

Who can take part

  • Pathologically proven diagnosis of squamous cell carcinoma of the head and neck (HNSCC) of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, or sinuses; Patients with oropharynx cancer need p16 determination by immunohistochemistry (where positive is defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells); Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer must be stages T1-2N1-3 or T3-4N0-3 (AJCC 8th edition). Sinus primary must be T4bN0-3 not amenable to surgical resection; P16-positive oropharynx cancer patients, stages T1-2N1-3 or T3-4N0-3 (AJCC 8th edition staging)
  • The patient has unresected, measurable disease as defined by the presence of at least one measurable lesion per RECIST 1.1
  • Age >= 18 years of age
  • Patients must have a contraindication to cisplatin
  • Performance Status of 0-2
  • Adequate hematologic function; White Blood Cell Count (WBC) >= 2000 cells/mm3; Absolute neutrophil count (ANC) >= 1,500 cells/mm3; Platelets >= 100,000 cells/mm3; Hemoglobin >= 9.0 g/dL
  • Adequate renal function was defined as follows: Creatinine clearance (CrCl) > 30 mL/min
  • Adequate hepatic function; Total bilirubin <= 1.5 x upper limit of normal (ULN) (except patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL); aspartate aminotransferase (AST) and alanine transaminase (ALT) <= 2.5 x upper limit of normal (ULN)
  • For women of childbearing potential (e.g. uterus present and menstruating), a negative serum pregnancy test within 14 days prior to registration
  • Willingness to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from time of joining the study until 6 months after completing chemotherapy treatment or 3 months after last dose of xevinapant, whichever is the latest
  • Patients with a history of hepatitis B or C infection are eligible if they have an undetectable viral load
  • Ability to understand and the willingness to sign a written informed consent document
  • Availability of tumor tissue for research analysis. Patients who do not have adequate tissue available will need to undergo a new biopsy prior to enrollment on study

Who cannot take part

  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable if not within < 3 years
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • Receipt of live vaccinations within 28 days prior to study start
  • Patients who are receiving any other investigational agents
  • Patients taking prohibited medications and those requiring close monitoring
  • Definitive clinical or radiologic evidence of distant (beyond cervical lymph node and neck tissue) metastatic disease
  • Severe, active co-morbidity defined as follows:; History of bone marrow transplant and organ transplant, including allogeneic stem cell transplantation; Unstable angina requiring hospitalization in the last 6 months; New York Heart Association Functional Classification III/IV; Myocardial infarction within the last 6 months; Persistent Grade 3-4 electrolyte abnormalities that cannot be reversed despite as indicated by repeat testing; Ongoing active infection associated with symptoms and/or requires antibiotic therapy at the time of initiation of treatment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to xevinapant, carboplatin, or paclitaxel
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years
  • Carcinoma of the neck of unknown primary site of origin
  • Pregnancy and nursing females, if applicable

Where in United States

  • University of Chicago Medicine-Comprehensive Cancer CenterChicago, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine the best safe dose of xevinapant that can be given in combination with chemotherapy and radiation in patients with head and neck cancer. Up to 4 doses of xevinapant will be tested in the dose escalation portion of the study. After the best safe dose is found during escalation, an additional group of participants will be enrolled at that dose to learn more about the treatment combination (dose expansion).

Read full original descriptionShow less

The main question[s] it aims to answer are:

* what is the maximum safe dose that can be given * what dose should be used in subsequent (phase 2) trials

Participants will receive xevinapant in combination with paclitaxel and carboplatin chemotherapy and radiation. Treatment will be given in 3-week cycles for 3 cycles.

The 5 groups in the trial

  • Escalation Group Dose Level -1Treatment being tested

    Participants assigned to this cohort will receive xevinapant 50 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT). An additional 3 cycles of xevinapant will be given after completion of chemoRT.

    Treatment: Xevinapant, Carboplatin, Paclitaxel, and Radiation Therapy

  • Escalation Group Dose Level 0Treatment being tested

    Participants assigned to this cohort will receive xevinapant 100 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT). An additional 3 cycles of xevinapant will be given after completion of chemoRT.

    Treatment: Xevinapant, Carboplatin, Paclitaxel, and Radiation Therapy

  • Escalation Group Dose Level 1Treatment being tested

    Participants assigned to this cohort will receive xevinapant 150 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT). An additional 3 cycles of xevinapant will be given after completion of chemoRT.

    Treatment: Xevinapant, Carboplatin, Paclitaxel, and Radiation Therapy

  • Escalation Group Dose Level 2Treatment being tested

    Participants assigned to this cohort will receive xevinapant 200 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT). An additional 3 cycles of xevinapant will be given after completion of chemoRT.

    Treatment: Xevinapant, Carboplatin, Paclitaxel, and Radiation Therapy

  • Dose ExpansionTreatment being tested

    Participants assigned to this cohort will receive xevinapant at the dose found during escalation phase of study for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT). An additional 3 cycles of xevinapant will be given after completion of chemoRT.

    Treatment: Xevinapant, Carboplatin, Paclitaxel, and Radiation Therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Study of Xevinapant With Radiation and Concurrent Carboplatin and Paclitaxel in Patients Ineligible for Cisplatin With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Record updated
31 March 2026